Scholars Central

Conference abstractPublished 21 Oct 2013

Can targeted/metabolic therapy outperform standard chemotherapy for Breast cancer in the post-op adjuvant setting? In vitro live cell analysis and clinical correlation in a Breast cancer patient

Authors: Akbar Khan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The diabetes drug metformin has been extensively researched as an anticancer therapy. Existing data suggests it may have a role in prevention and also in treatment, as an adjuvant to other therapies. In a recent publication ( Individualizing Chemotherapy using the Anti-Diabetic Drug, Metformin, as an ?Adjuvant?: An Exploratory Study. J Cancer SciTher 5:120-125.) Khan and Bradford demonstrated the potential widespread role of metformin in cancer treatment using human cells in vitro . Metformin was also shown to potentiate the metabolic therapy dichloroacetate. A 51 year old patient with intraductal breast carcinoma requested ChemoFitTMlive cell chemo sensitivity testing at the time of lumpectomy. Based on this, it was determined that a combination of metformin + dichloroacetate outperformed various standard chemotherapy cocktails approved breast cancer treatment (in terms of % cell kill). The patient was treated with oral dichloroacetate + metformin for 3 months. The patient developed moderate peripheral neuropathy from the dichloroacetate and the therapy was otherwise well-tolerated. MainTrac TM circulating tumor cell counts were taken pre- and post-treatment. The patient achieved a surprising result: A reduction of circulating tumor cell count from 1050 cells per cc of blood to 50 cells per cc of blood (a 21x reduction). There was no nausea/vomiting, infection, hair loss, marrow injury, hepatic injury or renal injury, due to the non-toxic nature of the therapy. The routine use of ChemoFit TM assay, testing non-toxic drugs (e.g. metformin, dichloroacetate) alongside conventional chemotherapies, has the potential to revolutionize post-operative adjuvant therapy of breast and other cancers.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Akbar Khan”